Recent

% | $
Quotes you view appear here for quick access.

Trius Therapeutics, AŞ Message Board

chiraag_19 24 posts  |  Last Activity: Jul 13, 2016 4:12 PM Member since: Mar 16, 2010
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • chiraag_19 chiraag_19 Jul 13, 2016 4:12 PM Flag

    Here is the link to take you back to the old msg baord

    finance.yahoo.com/mb/exel/?bypass=true#morequotes

    Whenever you want to go to some board replaced the exel by that stock symbol. also type in http://

  • Reply to

    hey maddi, incyte was trading at 118 on dec 16

    by tjnelis Jul 8, 2016 3:25 PM
    chiraag_19 chiraag_19 Jul 11, 2016 2:16 PM Flag

    IBb and XBI collapsed. All drug stocks are down 50% or more. Incyte is the best of developing biotech breed

  • Reply to

    BuyOut this weekend:):):)

    by stent_tech_101 Jul 8, 2016 12:27 PM
    chiraag_19 chiraag_19 Jul 11, 2016 12:28 PM Flag

    And I'm disappointed today!

    Sentiment: Hold

  • Reply to

    BuyOut this weekend:):):)

    by stent_tech_101 Jul 8, 2016 12:27 PM
    chiraag_19 chiraag_19 Jul 9, 2016 5:43 PM Flag

    Every Friday is a buyout rumor day. Every Monday morning I'm so excited but only to be disappointed ( sarcasm intended)

  • Reply to

    Sold this turd.

    by awesomeone1955 Jul 8, 2016 10:39 AM
    chiraag_19 chiraag_19 Jul 8, 2016 12:47 PM Flag

    Good luck! It will never hit there pending a bad news. Biotech sector is coming up. If you think about it everything except biotech and oil were running up . Now those are overbought and people are looking for bargains and people are looking at biotech. Oil ran way too much in short time so there is no reason to put money there.

    By the way it just ran up to 150 after you sold. Tells you that you should never chase stock in hopes of buyout.

  • Reply to

    So I'll add at these levels $6.40

    by akanz2 Jun 17, 2016 2:32 PM
    chiraag_19 chiraag_19 Jul 7, 2016 2:15 PM Flag

    What do you think of RLYP and KERX? You made out like a bandit on ZS

  • Reply to

    Frankie's desire become truth

    by frankie1x Jun 29, 2016 3:49 PM
    chiraag_19 chiraag_19 Jun 30, 2016 1:01 PM Flag

    maybe two completely different drug and hence difference of opinion. Ocaliva targets PBC/NASH liver disease and it makes sense that they hired Gilead's point person for HepC launch in Europe.

    Jermasek was instrumental in establishing renal business for KErx so perfect fit for both.

  • Reply to

    ICPT is the only player on the field.

    by biotechhead Jun 9, 2016 9:27 AM
    chiraag_19 chiraag_19 Jun 9, 2016 12:20 PM Flag

    Exactly...And here is the quote

    "And then the other question was, why do I believe that simtuzumab will work in liver fibrosis even though it hasn’t shown to be active in IPF myelofibrosis and in tumors. What a simple reason is you could make an argument and therefore fibrosis is different from IPL. Buy having that said it is somewhat liver fibrosis it’s different from IPF. But having that said, it somewhat diminishes my enthusiasm about simtuzumab, because it’s simply hasn’t shown any activity yet in any of the diseases that we chose to do"

    So Even Bischofberger think that this is a really a toss up now with deck stacked heavily against it. it is going to fail in both..mark it down.

  • Reply to

    ICPT is the only player on the field.

    by biotechhead Jun 9, 2016 9:27 AM
    chiraag_19 chiraag_19 Jun 9, 2016 11:16 AM Flag

    Gilead is looking into PSC with their simtuzumab. PSC is brother disease of PBC. SO if they success in PSC they will succeed in PBC as well.

  • Reply to

    ICPT is the only player on the field.

    by biotechhead Jun 9, 2016 9:27 AM
    chiraag_19 chiraag_19 Jun 9, 2016 11:09 AM Flag

    Again a lit. Here is the actual quote" CA is a bile acid and bile acids do many things in your body and side effects that we’re seeing the rash". FDA approved OCA for PBC...where Rash is actually one of the symptoms. So another lie for you.

    "There was also a side effect of reducing HDL fairly substantially and we have the philosophy instead of dealing with an orally absorbed systemically active bile acid analog we have an FXR agonist that’s minimally, orally absorbed that simply works into GI and releases FGF19."

    Again no words of bad safety profile. The drug will be absorbed in liver and guess where is the HDL/LDL is processed..in the liver. So where you have a targeted approach it wills till end up interfering the lipid processing if it hits the same pathway.

    Divray you are such a big lier and then you have audacity to claim that you are fact abased.

  • chiraag_19 chiraag_19 Jun 9, 2016 10:38 AM Flag

    And this is a blatant lie. He did not refer to any drug esp about OCA and never mentioned the safety profile.

    It's OK. Ultimately you have to do your own homework and be fine with your position. I'm good with my position

    Sentiment: Hold

  • Reply to

    Shorting here is a guaranteed loss

    by awesomeone1955 Jun 8, 2016 9:50 AM
    chiraag_19 chiraag_19 Jun 8, 2016 11:22 PM Flag

    I am not sure. Generally bioteck sector is looking up. Trump and CLlnton are tearing into each other so it is less policy and more barking. Oil money has been made. I would not short here because the risk is too high. Look at IBB for clues.

    Sentiment: Hold

  • Reply to

    Couple of observations

    by chiraag_19 Jun 8, 2016 10:34 AM
    chiraag_19 chiraag_19 Jun 8, 2016 11:00 AM Flag

    And Jonathan Silverstein is the managing partner of Orbimed who made this investment. He also has and I quote"1,259 shares of common stock and options to purchase 15,327 shares of common stock that are exercisable within 60 days of May 23, 2016 that are held directly by Mr. Silverstein. Look at the date 23rd May2016. Calculate 60 days from here that takes us to July 26th. If he exercises his right to buy you could bet your house that buyout is in process in next 2 months after July 26th .

    Sentiment: Hold

  • chiraag_19 by chiraag_19 Jun 8, 2016 10:34 AM Flag

    None of the insiders have sold any shares after approval. They could have easily timed it esp Dr. Shapiro. If you go back and look in the past every major run up has saw insiders esp Shapiro unloading few shares. That will tell you something.

    Second look at the ownership of the shares. Orbimed is almost a 55 owner and I'm delightfully surprise to see FMT with 14% ownership of share! That is again a vote of confidence.

    Third the pipeline is exciting. Look at harvoni/Sovaldi. Gilead made money of 1st Generation and the of 2nd generation and are right behind the 3rd generation combo. if there second molecule pans out they will have a long sustainable drug product with potential combination. Gilead also has atleast three other drugs that target other receptors in the same pathway so combinations are more likely to happen.

    i know some of you have been playing weekly buyout games. It will not do you good. You buy and hold your core and make money on trading your shares.

    buyout will happen before year end. My timeline is August/September when they have some idea on the new molecule is #$%$ and how the lipid studies are going on.

    If you are looking for buyout candidates here are coupleof nuggets. Always look for companies who have de-risked drugs that means they have done atleast phase 2 with a clear efficacy signal. Second they lack commercial infrastructure to launch drugs by themselves. third they have fewer competitors int he same disease with potential to launch in other indications. This applies to a lesser extend to oncology companies but still is true.

  • Reply to

    Seymour...where are u

    by drscottpalmer Jun 6, 2016 10:25 PM
    chiraag_19 chiraag_19 Jun 7, 2016 9:47 AM Flag

    Oh man....Sun will always set in west and Uling will always be there to defend Seymour.

    Sentiment: Hold

  • Reply to

    Question about pricing?

    by dip_199 Jun 3, 2016 9:24 AM
    chiraag_19 chiraag_19 Jun 3, 2016 1:58 PM Flag

    Also one critical problem with Provenge was the manufacturing cost. It was expensive and not any operating margin left int here to make any money. This will be a pill so easy. The real money make will be NASH. if it hits NASH, lipid trial shows no safety concern and the second compound is better than OCA then we can say this will be 500 dollar stock at minimum.

    Sentiment: Hold

  • Reply to

    Question about pricing?

    by dip_199 Jun 3, 2016 9:24 AM
    chiraag_19 chiraag_19 Jun 3, 2016 1:56 PM Flag

    People who have insurance and want to stay alive will pay the price. The good thing is insurance cover most of it. And people who don't have insurance can always go through charity and get the cost reduced.

    Sentiment: Hold

  • Reply to

    Question about pricing?

    by dip_199 Jun 3, 2016 9:24 AM
    chiraag_19 chiraag_19 Jun 3, 2016 1:54 PM Flag

    What! That is just a buffoonery argument you provided. Go back and check the cost of MS drugs as well as Oncology. Look at the total care that goes into costs. Insurance never pays what the list price is. It is always negotiated and to reduce the companies provide rebates.

    From your argument it is clear that you are a short or long Genfit. Good luck.

  • Reply to

    berens what a phony

    by what_a_manipulation Jun 2, 2016 3:44 PM
    chiraag_19 chiraag_19 Jun 2, 2016 4:01 PM Flag

    Not to mention KERX as well...

  • chiraag_19 by chiraag_19 Jun 2, 2016 4:00 PM Flag

    I think buyout is in works now. there is no worthy news except buyout